WallStSmart

Bio-Rad Laboratories Inc (BIO)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 152% more annual revenue ($6.51B vs $2.59B). EW leads profitability with a 15.4% profit margin vs 8.6%. BIO appears more attractively valued with a PEG of 1.19. EW earns a higher WallStSmart Score of 55/100 (C).

BIO

Buy

55

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 4.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.36

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BIOSignificantly Overvalued (-46.5%)

Margin of Safety

-46.5%

Fair Value

$200.53

Current Price

$369.32

$168.79 premium

UndervaluedFair: $200.53Overvalued
EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIO3 strengths · Avg: 9.7/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.3610/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Areas to Watch

BIO4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
46.2x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BIO

The strongest argument for BIO centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bear Case : BIO

The primary concerns for BIO are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 46.2x leaves little room for execution misses.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Key Dynamics to Monitor

BIO profiles as a value stock while EW is a mature play — different risk/reward profiles.

BIO carries more volatility with a beta of 1.07 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

BIO scores higher overall (55/100 vs 55/100). EW offers better value entry with a 68.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bio-Rad Laboratories Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?